Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ferumoxytol MRI for Pediatric Brain Tumor Blood Volume Mapping
NCT03234309Phase 2Withdrawn
- Sponsor
- OHSU Knight Cancer Institute
- Start
- Oct 2017
- Primary completion
- Aug 2021
01
Overview
Phase 2, open-label trial of ferumoxytol in brain neoplasm, sponsored by OHSU Knight Cancer Institute. Primary endpoints: Overlay accuracy with 3-dimensional anatomical T1w post contrast scans at 5 years and Confidence in identifying the lesion corresponding areas on cerebral blood volume maps at 5 years. Planned start Oct 2017; status: withdrawn.
02
Drugs
ferumoxytol
03
Conditions
brain neoplasm
Beyond the preview
Go deeper on NCT03234309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03234309.